Second-line oral vinorelbine following first-line platinum and pemetrexed in malignant pleural mesothelioma

European journal of Clinical and Medical Oncology

Volumn 4, Issue 4, 2012, Pages

  Sørensen, Jens Benn ^a   Urbanska, Edyta ^a   Langer, Seppo W ^a   Aamdal, Elin ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Second line; Vinorelbine

Indexed keywords

EID: 84876556434     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183-1185.
2. Ceresoli GL, Betta GP, Castagneto B, et al. Malignant pleural mesothelioma. Ann Oncol. 2006;17:13-16.
3. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer. 2004;455:S103-S109.
4. Sørensen JB. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J. 2008;2:74-79.
5. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556-1561.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
7. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung cancer. 2002;38:111-121.
8. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006;1:591-601.
9. Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912-3917.
10. Muers MF, Stephens RJ, Fisher P, et al. MS01 trial management group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371:1685-1694.
11. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first line chemotherapy in malignant pleural mesothelioma (MPM). Brit J Cancer. 2008;99:44-50.
12. Sørensen JB, Sørensen P, Frank H. Carboplatin and vinorelbine first line chemotherapy in malignant pleural mesothelioma (MPM). In: Proceedings of the World conference on mesothelioma (IMIG), Kyoto, Japan 2010, abstract 56.
13. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63:94-97.
14. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122-1128.
15. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15: 257-260.
16. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thoracic Oncol. 2008;3:1325-1331.
17. Jänne PA, Wozniak AJ, Bellini CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506-512.
18. Sørensen JB, Sundstrøm S, Perell K, Thielsen AK. Pemetrexed as second line treatment in malignant pleural mesothelioma after platinum based first line treatmment. J Thorac Oncol. 2007;2:147-152.
19. Taylor P, Castagneto B, Dark G, et al. Single agent pemetrexed for chemonai{dotless}̈ve and pretreated patients with malignant pleural mesothe-lioma: results of an international expanded access program. J Thorac Oncol. 2008;3:764-771.
20. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 26:1698-1704.
21. Serke M, Bauer T. Pemetrexed in second line therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2007;25(18s):abstr. 18198.
22. De Vincenzo F, Zucali PA, Ceresoli GL, et al. Re treatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. In: Proceedings of the IMIG (International Mesothelioma Interest Group), Amsterdam2008; abstr. 163.
23. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schonfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008;3:34-41.
24. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555-1561.
25. Zucali PA, Lorenzi E, Ceresoli G et al. Vinorelbine (V) in pemetrexed pretreated patients (PTS) with malignant pleural mesothelioma (MPM). In: Proceedings of the 10th International Conference of the International Mesothelioma Interest Group, Kyoyo, Japan 2010: abstr. 104.
26. Giaccone G, O'Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B. Phase II trial of ZD0473 as second line therapy in mesothelioma. Eur J Cancer. 2002;38:19-24.
27. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003;21:349-354.
28. Porta C, Zimatore M, Bonomi L, et al. Raltitrexed oxaliplatin combination chemotherapy is inactive as second line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005;48:429-434.
29. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first or second line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007;109:93-99.
30. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. Second line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010;36:24-32.